Magnetic hydroxyapatite nanomaterial–cyclodextrin tethered polymer hybrids as anticancer drug carriers

Ramasamy, Sivaraj; Dhamecha, Dinesh; Kaliyamoorthi, Kiruthiga; Pillai, Archana Sumohan; Alexander, Aleyamma; Dhanaraj, Premnath; Menon, Jyothi U.; Enoch, Israel V.M.V.

doi:10.1039/d1ma00142f

Cited by 21 publications

(10 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If it happens, the amount of concentration required is a bit high; however, approaches should be made through the targeted drug delivery to breast cancer which is yet to be studied. This issue could be remedied by increasing diosgenin's cellular permeability and promoting anti-cancer action against breast tumors via a novel drug delivery mechanism, as established in previous studies (Dhamecha et al, 2015;Jagwani et al, 2020;Dhamecha et al, 2021;Ramasamy et al, 2021). In addition, the effect of diosgenin on the hub genes (SRC, MDM2, and IGF1R) expression is based on the computational models which need to be further evaluated using real-time or reverse transcriptase polymerase chain reaction even though the present study pointed their functional effect via the glucose uptake, cell proliferation, and apoptosis which is the perspective of the present findings.…”

Section: Discussionmentioning

confidence: 99%

Systems and in vitro pharmacology profiling of diosgenin against breast cancer

Khanal

Patil²,

Bhandare

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Aim: The purpose of this study was to establish a mode of action for diosgenin against breast cancer employing a range of system biology tools and to corroborate its results with experimental facts.Methodology: The diosgenin-regulated domains implicated in breast cancer were enriched in the Kyoto Encyclopedia of Genes and Genomes database to establish diosgenin-protein(s)-pathway(s) associations. Later, molecular docking and the lead complexes were considered for molecular dynamics simulations, MMPBSA, principal component, and dynamics cross-correlation matrix analysis using GROMACS v2021. Furthermore, survival analysis was carried out for the diosgenin-regulated proteins that were anticipated to be involved in breast cancer. For gene expression analyses, the top three targets with the highest binding affinity for diosgenin and tumor expression were examined. Furthermore, the effect of diosgenin on cell proliferation, cytotoxicity, and the partial Warburg effect was tested to validate the computational findings using functional outputs of the lead targets.Results: The protein-protein interaction had 57 edges, an average node degree of 5.43, and a p-value of 3.83e-14. Furthermore, enrichment analysis showed 36 KEGG pathways, 12 cellular components, 27 molecular functions, and 307 biological processes. In network analysis, three hub proteins were notably modulated: IGF1R, MDM2, and SRC, diosgenin with the highest binding affinity with IGF1R (binding energy −8.6 kcal/mol). Furthermore, during the 150 ns molecular dynamics (MD) projection run, diosgenin exhibited robust intermolecular interactions and had the least free binding energy with IGF1R (−35.143 kcal/mol) compared to MDM2 (−34.619 kcal/mol), and SRC (-17.944 kcal/mol). Diosgenin exhibited the highest cytotoxicity against MCF7 cell lines (IC50 12.05 ± 1.33) µg/ml. Furthermore, in H2O2-induced oxidative stress, the inhibitory constant (IC50 7.68 ± 0.51) µg/ml of diosgenin was lowest in MCF7 cell lines. However, the reversal of the Warburg effect by diosgenin seemed to be maximum in non-cancer Vero cell lines (EC50 15.27 ± 0.95) µg/ml compared to the rest. Furthermore, diosgenin inhibited cell proliferation in SKBR3 cell lines more though.Conclusion: The current study demonstrated that diosgenin impacts a series of signaling pathways, involved in the advancement of breast cancer, including FoxO, PI3K-Akt, p53, Ras, and MAPK signaling. Additionally, diosgenin established a persistent diosgenin-protein complex and had a significant binding affinity towards IGF1R, MDM2, and SRC. It is possible that this slowed down cell growth, countered the Warburg phenomenon, and showed the cytotoxicity towards breast cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Systems and in vitro pharmacology profiling of diosgenin against breast cancer

Khanal

Patil²,

Bhandare

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Enhanced activity was observed in the case of the DOX-loaded Sr, FeHAp. The NHs proved to be good nanocarriers for cancer therapy and further clinical studies can determine their possible use [ 68 ]. A generalized structure of chitosan-based nanohybrids is given in Figure 3 .…”

Section: Carbohydrate Polymer-basednhsmentioning

confidence: 99%

Polymer-Based Hybrid Nanoarchitectures for Cancer Therapy Applications

et al. 2022

View full text Add to dashboard Cite

Globally, cancer is affecting societies and is becoming an important cause of death. Chemotherapy can be highly effective, but it is associated with certain problems, such as undesired targeting and multidrug resistance. The other advanced therapies, such as gene therapy and peptide therapy, do not prove to be effective without a proper delivery medium. Polymer-based hybrid nanoarchitectures have enormous potential in drug delivery. The polymers used in these nanohybrids (NHs)provide them with their distinct properties and also enable the controlled release of the drugs. This review features the recent use of polymers in the preparation of different nanohybrids for cancer therapy published since 2015 in some reputed journals. The polymeric nanohybrids provide an advantage in drug delivery with the controlled and targeted delivery of a payload and the irradiation of cancer by chemotherapeutical and photodynamic therapy.

show abstract

“…Although a cytotoxic effect was evidenced against lung, cervical, liver and bone cancer cells in vitro , an enhanced toxicity was reported on the osteosarcoma MG-63 cells. The nanohybrid was further tested on male and female albino mice, corroborating the antitumoral potential [ 93 ].…”

Section: Functionalization Of Hap and Inclusion Into Biopolymer Matri...mentioning

confidence: 99%

Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer

Lama-Odría

Valle

Puiggalı́

2022

IJMS

View full text Add to dashboard Cite

Great advances in cancer treatment have been undertaken in the last years as a consequence of the development of new antitumoral drugs able to target cancer cells with decreasing side effects and a better understanding of the behavior of neoplastic cells during invasion and metastasis. Specifically, drug delivery systems (DDS) based on the use of hydroxyapatite nanoparticles (HAp NPs) are gaining attention and merit a comprehensive review focused on their potential applications. These are derived from the intrinsic properties of HAp (e.g., biocompatibility and biodegradability), together with the easy functionalization and easy control of porosity, crystallinity and morphology of HAp NPs. The capacity to tailor the properties of DLS based on HAp NPs has well-recognized advantages for the control of both drug loading and release. Furthermore, the functionalization of NPs allows a targeted uptake in tumoral cells while their rapid elimination by the reticuloendothelial system (RES) can be avoided. Advances in HAp NPs involve not only their use as drug nanocarriers but also their employment as nanosystems for magnetic hyperthermia therapy, gene delivery systems, adjuvants for cancer immunotherapy and nanoparticles for cell imaging.

show abstract

Magnetic hydroxyapatite nanomaterial–cyclodextrin tethered polymer hybrids as anticancer drug carriers

Abstract: Osteosarcoma, the most common bone cancer, leads to a poor survival rate of patients. Drug targeting employing hydroxyapatite (HAp)-based nanocarriers represents a fascinating choice for non-invasive treatment of osteosarcoma. Herein,...

Cited by 21 publications

References 59 publications

Systems and in vitro pharmacology profiling of diosgenin against breast cancer

Systems and in vitro pharmacology profiling of diosgenin against breast cancer

Polymer-Based Hybrid Nanoarchitectures for Cancer Therapy Applications

Hydroxyapatite Biobased Materials for Treatment and Diagnosis of Cancer

Contact Info

Product

Resources

About